Inhaled corticosteroid treatment and pneumonia in patients with chronic obstructive pulmonary disease – nationwide development from 1998 to 2018

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2023 report). Global Initiative for Chronic Obstructive Lung Disease; 2023.
   Google Scholar
• Quint JK, Ariel A, Barnes PJ. Rational use of inhaled corticosteroids for the treatment of COPD. NPJ Prim Care Respir Med. 2023 Jul 24;33(1):27. doi: 10.1038/s41533-023-00347-6
   PubMed Web of Science ®Google Scholar
• Alter P, Kahnert K, Trudzinski FC, et al. Clinical factors linked to the type of respiratory medication in COPD: results from the COSYCONET cohort. Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231208584. doi: 10.1177/17534666231208584
   Web of Science ®Google Scholar
• Fukuda N, Horita N, Kaneko A, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2023 Jun 5;6(6):Cd012066. doi: 10.1002/14651858.CD012066.pub3
   PubMedGoogle Scholar
• Miravitlles M, Verhamme K, Calverley PMA, et al. A pooled analysis of mortality in patients with COPD receiving dual bronchodilation with and without additional inhaled corticosteroid. Int J Chron Obstruct Pulmon Dis. 2022;17:545–10. doi: 10.2147/COPD.S350167
   PubMed Web of Science ®Google Scholar
• Oba Y, Keeney E, Ghatehorde N, et al. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2018 Dec 3;12(12):Cd012620. doi: 10.1002/14651858.CD012620.pub2
   PubMed Web of Science ®Google Scholar
• Vestbo J. Fixed triple therapy in chronic obstructive pulmonary disease and survival. Living better, longer, or both? Am J Respir Crit Care Med. 2020 Jun 15;201(12):1463–1464. doi: 10.1164/rccm.202003-0622ED
   PubMed Web of Science ®Google Scholar
• Lu C, Mao X. Risk of adverse reactions associated with inhaled corticosteroids for chronic obstructive pulmonary disease: A meta-analysis. Medicine (Baltimore). 2024 Jan 19;103(3):e36609. doi: 10.1097/MD.0000000000036609
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Auladell-Rispau A, Monteagudo M, et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Rev. 2021 Jun 30;30(160):210075. doi: 10.1183/16000617.0075-2021
   PubMed Web of Science ®Google Scholar
• Klitgaard A, Ibsen R, Lykkegaard J, et al. National development in the use of inhaled corticosteroid treatment in chronic obstructive pulmonary disease: repeated cross-sectional studies from 1998 to 2018. Biomedicines. 2024;12(2):372. doi: 10.3390/biomedicines12020372
   PubMed Web of Science ®Google Scholar
• Janson C, Johansson G, Ställberg B, et al. Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational study. Respir Res. 2018 Sep 10;19(1):172. doi: 10.1186/s12931-018-0868-y
   PubMed Web of Science ®Google Scholar
• Lee EG, Kim Y, Hwang YI, et al. Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD. Sci Rep. 2023 May 20;13(1):8183. doi: 10.1038/s41598-023-35223-3
   PubMed Web of Science ®Google Scholar
• Chen H, Sun J, Huang Q, et al. Inhaled corticosteroids and the pneumonia risk in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Front Pharmacol. 2021;12:691621. doi: 10.3389/fphar.2021.691621
   PubMed Web of Science ®Google Scholar
• Vestbo J, Waterer G, Leather D, et al. Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD. Eur Respir J. 2022 May;59(5):2102899. doi: 10.1183/13993003.02899-2021
   PubMed Web of Science ®Google Scholar
• Søgaard M, Madsen M, Løkke A, et al. Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia. Int J Chron Obstruct Pulmon Dis. 2016;11:455–465. doi: 10.2147/COPD.S96179
   PubMed Web of Science ®Google Scholar
• Steer J, Norman EM, Afolabi OA, et al. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. Thorax. 2012 Feb;67(2):117–121. doi: 10.1136/thoraxjnl-2011-200332
   PubMed Web of Science ®Google Scholar
• Reilev M, Pottegård A, Davidsen JR, et al. Seventeen-year nationwide trends in use of long-acting bronchodilators and inhaled corticosteroids among adults - a Danish drug utilization study. Basic Clin Pharmacol Toxicol. 2018 Jul;123(1):58–64. doi: 10.1111/bcpt.12978
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schmidt SA, Sandegaard JL, et al. The Danish national patient registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490. doi: 10.2147/CLEP.S91125
   PubMed Web of Science ®Google Scholar
• Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, et al. Data resource profile: the danish national prescription registry. Int J Epidemiol. 2017 Jun 1;46(3):798–f. doi: 10.1093/ije/dyw213
   PubMed Web of Science ®Google Scholar
• Kildemoes HW, Sørensen HT, Hallas J. The Danish national prescription registry. Scand J Public Health. 2011 Jul;39(7 Suppl):38–41. doi: 10.1177/1403494810394717
   PubMed Web of Science ®Google Scholar
• Jensen VM, Rasmussen AW. Danish education registers. Scand J Public Health. 2011 Jul;39(7 Suppl):91–94. doi: 10.1177/1403494810394715
   PubMed Web of Science ®Google Scholar
• Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health. 2011 Jul;39(7 Suppl):103–105. doi: 10.1177/1403494811405098
   PubMed Web of Science ®Google Scholar
• Mainz J, Hess MH, Johnsen SP. The Danish unique personal identifier and the Danish civil registration system as a tool for research and quality improvement. Int J Qual Health Care. 2019 Nov 30;31(9):717–720. doi: 10.1093/intqhc/mzz008
   PubMed Web of Science ®Google Scholar
• Håkansson KEJ, Løkke A, Ibsen R, et al. Beyond direct costs: individual and societal financial burden of asthma in young adults in a Danish nationwide study. BMJ Open Respir Res. 2023 May;10(1):e001437. doi: 10.1136/bmjresp-2022-001437
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Inhaled corticosteroid doses for NICE’s asthma guideline [Dosage Comparison Chart; from NICE’s guideline “Asthma: diagnosis, Monitoring and Chronic Management”]. National Institute for Health and Care Excellence (NICE). 2018.
   Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med care. 2005 Nov;43(11):1130–1139. doi: 10.1097/01.mlr.0000182534.19832.83
   PubMed Web of Science ®Google Scholar
• Thygesen SK, Christiansen CF, Christensen S, et al. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish national registry of patients. BMC Med Res Methodol. 2011 May 28;11(1):83. doi: 10.1186/1471-2288-11-83
   PubMed Web of Science ®Google Scholar
• Boers E, Barrett M, Su JG, et al. Global burden of chronic obstructive pulmonary disease through 2050. JAMA Netw Open. 2023 Dec 1;6(12):e2346598. doi: 10.1001/jamanetworkopen.2023.46598
   PubMed Web of Science ®Google Scholar
• Benjafield A, Tellez D, Barrett M, et al. An estimate of the European prevalence of COPD in 2050. Eur Respir J. 2021;58(suppl 65):OA2866.
   Google Scholar
• van Oostrom SH, Gijsen R, Stirbu I, et al. Time trends in prevalence of chronic diseases and multimorbidity not only due to aging: data from general practices and health surveys. PLOS ONE. 2016;11(8):e0160264. doi: 10.1371/journal.pone.0160264
   PubMed Web of Science ®Google Scholar
• Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. Eur J Gen Pract. 2008;14 Suppl 1(sup1):28–32. doi: 10.1080/13814780802436093
   PubMedGoogle Scholar
• Meinow B, Parker MG, Kåreholt I, et al. Complex health problems in the oldest old in Sweden 1992-2002. Eur J Ageing. 2006 Jun;3(2):98–106. doi: 10.1007/s10433-006-0027-z
   PubMedGoogle Scholar
• Walters JA, Tang JN, Poole P, et al. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 Jan 24;1(1):Cd001390. doi: 10.1002/14651858.CD001390.pub4
   PubMed Web of Science ®Google Scholar
• Kantsø B. Pneumokokvaccination uden for børnevaccinationsprogrammet i Danmark. Version 1.3. Statens Serum Institut, 2014 2014.09.24. Report No.
   Google Scholar
• Danish Ministry of Health. National action plan on antibiotics in human healthcare. Danish Ministry of Health; 2017.
   Google Scholar
• Statens Serum Institut and The National Food Institute, Technical University of Denmark. DANMAP 2021 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. Statens Serum Institut and The National Food Institute, Technical University of Denmark; 2021. ISSN 1600-2032.
   Google Scholar
• Søgaard M, Nielsen RB, Schønheyder HC, et al. Nationwide trends in pneumonia hospitalization rates and mortality, Denmark 1997-2011. Respir med. 2014 Aug;108(8):1214–1222. doi: 10.1016/j.rmed.2014.05.004
   PubMed Web of Science ®Google Scholar
• Hurst JR, Skolnik N, Hansen GJ, et al. Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. Eur J Intern Med. 2020 Mar;73:1–6. doi: 10.1016/j.ejim.2019.12.014
   PubMed Web of Science ®Google Scholar
• Müllerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir med. 2012 Aug;106(8):1124–1133. doi: 10.1016/j.rmed.2012.04.008
   PubMed Web of Science ®Google Scholar
• Suissa S, Coulombe J, Ernst P. Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia. Chest. 2015 Nov;148(5):1177–1183. doi: 10.1378/chest.15-0627
   PubMed Web of Science ®Google Scholar
• Yawn BP, Suissa S, Rossi A. Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal. NPJ Prim Care Respir Med. 2016 Sep 29;26(1):16068. doi: 10.1038/npjpcrm.2016.68
   PubMedGoogle Scholar
• Dransfield MT, Crim C, Criner GJ, et al. Risk of exacerbation and pneumonia with single-inhaler triple versus dual therapy in IMPACT. Ann Am Thorac Soc. 2021 May;18(5):788–798. doi: 10.1513/AnnalsATS.202002-096OC
   PubMed Web of Science ®Google Scholar
• Williams NP, Ostridge K, Devaster J-M, et al. Impact of radiologically stratified exacerbations: insights into pneumonia aetiology in COPD. Respir Res. 2018 July 28;19(1):143. doi: 10.1186/s12931-018-0842-8
   PubMed Web of Science ®Google Scholar
• Lineros R, Fernández-Delgado L, Vega-Rioja A, et al. Associated factors of pneumonia in individuals with Chronic Obstructive Pulmonary Disease (COPD) apart from the use of inhaled corticosteroids. Biomedicines. 2023 Apr 22;11(5):1243. doi: 10.3390/biomedicines11051243
   PubMed Web of Science ®Google Scholar
• Festic E, Bansal V, Gupta E, et al. Association of Inhaled corticosteroids with incident pneumonia and mortality in COPD patients; systematic review and meta-analysis. COPD: J Chronic Obstructive Pulmonary Dis. 2016 Jun;13(3):312–326. doi: 10.3109/15412555.2015.1081162
   PubMed Web of Science ®Google Scholar
• Contoli M, Corsico AG, Santus P, et al. Use of ICS in COPD: From blockbuster medicine to precision medicine. COPD: J Chronic Obstructive Pulmonary Dis. 2017 Dec;14(6):641–647. doi: 10.1080/15412555.2017.1385056
   PubMed Web of Science ®Google Scholar
• van Geffen WH, Tan DJ, Walters JA, et al. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2023 Dec 6;12(12):Cd011600. doi: 10.1002/14651858.CD011600.pub3
   PubMedGoogle Scholar
• Schmidt M, Schmidt SAJ, Adelborg K, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563–591. doi: 10.2147/CLEP.S179083
   PubMed Web of Science ®Google Scholar
• van Vugt SF, Verheij TJ, de Jong PA, et al. Diagnosing pneumonia in patients with acute cough: clinical judgment compared to chest radiography. Eur Respir J. 2013 Oct;42(4):1076–1082. doi: 10.1183/09031936.00111012
   PubMed Web of Science ®Google Scholar
• Lykkegaard J, Nielsen JB, Storsveen MM, et al. Healthcare costs of patients with chronic obstructive pulmonary disease in Denmark - specialist care versus GP care only. BMC Health Serv Res. 2022 Mar 28;22(1):408. doi: 10.1186/s12913-022-07778-w
   PubMed Web of Science ®Google Scholar
• Savran O, Godtfredsen N, Sørensen T, et al. Characteristics of COPD patients prescribed ICS managed in general practice vs. Secondary care. COPD: J Chronic Obstructive Pulmonary Dis. 2021 Nov 03;18(5):493–500. doi: 10.1080/15412555.2021.1970737
   PubMed Web of Science ®Google Scholar
• Nørgaard M, Johnsen SP. How can the research potential of the clinical quality databases be maximized? The Danish experience. J Intern Med. 2016 Feb;279(2):132–140. doi: 10.1111/joim.12437
   PubMed Web of Science ®Google Scholar
• Wise RA, Bafadhel M, Crim C, et al. Discordant diagnostic criteria for pneumonia in COPD trials: a review. Eur Respir Rev. 2021 Dec 31;30(162):210124. doi: 10.1183/16000617.0124-2021
   PubMed Web of Science ®Google Scholar